In newly diagnosed asymptomatic T2DM patients with HbA1c ≥9%, treatment may be started with a triple-drug single-pill combination of metformin, DPP-4 inhibitor, and SGLT-2 inhibitor. Here, SLC5A2 is linked to type 2 diabetes mellitus.